Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477160 · ClinicalTrials.gov registry record · Phase 1
A Study of STAR-0215 in Healthy Adult Participants
A Phase 1 study, sponsored by Astria Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT05477160: Completed Phase 1 study, sponsored by Astria Therapeutics.
NCT05477160 is a Phase 1 study that has completed, run by Astria Therapeutics. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05477160, a Phase 1 study, has completed, sponsored by Astria Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous (SC) or intravenous (IV) administration of STAR-0215 in healthy adult participants.
Interventions
- DRUG Placebo (SC)
- DRUG Placebo (IV)
- DRUG STAR-0215 (SC)
- DRUG STAR-0215 (IV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-07-27 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 1 |
What the finished NCT05477160 record still lists
NCT05477160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo (SC) is the first listed.
NCT05477160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05477160 about?
NCT05477160 is a clinical study titled "A Study of STAR-0215 in Healthy Adult Participants". This is a first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous (SC) or intravenous (IV) administration of STAR-0215 in healthy adul...
What is the current status of trial NCT05477160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2022-07-27. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT05477160?
The interventions under investigation include: Placebo (SC) (DRUG), Placebo (IV) (DRUG), STAR-0215 (SC) (DRUG), STAR-0215 (IV) (DRUG).
Who is sponsoring clinical trial NCT05477160?
This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05477160's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI